EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Results of Operations and Financial Condition

Item 2.02Results of Operations and Financial Condition.

On January 9, 2017, Evoke Pharma, Inc. (the Company or Evoke),
announced that its preliminary unaudited cash and cash
equivalents as of December 31, 2016 were approximately $9.0
million.

The preliminary unaudited cash position discussed above is
subject to the completion of financial closing procedures and
other developments that may arise between now and the time the
financial results for the fourth quarter are finalized, as well
as the completion of the audit of the 2016 financial statements.
Therefore, actual results may differ materially from these
estimates. In addition, the above estimates do not present all
information necessary for an understanding of Evokes financial
condition as of December 31, 2016.

In accordance with General Instruction B.2 of Form 8-K, the
information in Item 2.02 of this Current Report on Form 8-K shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended (the Securities Act), or the Exchange Act,
whether made before or after the date hereof, except as expressly
set forth by specific reference in such filing to this Current
Report on Form

Item 7.01Regulation FD Disclosure.

Beginning on January 9, 2017, representatives of Evoke will be
attending meetings with investors, analysts and other parties in
connection with the J.P. Morgan 34th Annual Healthcare Conference
in San Francisco, California.During these meetings, Evoke will
present the slides attached as Exhibit 99.1 to this Current
Report on Form 8-K, which are incorporated by reference.

The information in this Item 7.01, including Exhibit 99.1, is
being furnished to Item 7.01 and shall not be deemed filed for
purposes of Section 18 of the Exchange Act or otherwise subject
to the liabilities of that section, and it shall not be deemed
incorporated by reference in any filing under the Securities Act,
whether made before or after the date hereof, except as expressly
set forth by specific reference in such filing to this item of
this report.

Forward Looking Statements.

The Company cautions you that statements included in this Current
Report on Form 8-K that are not a description of historical facts
are forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential” or
“continue” or the negatives of these terms or other similar
expressions. These statements are based on the Company’s current
beliefs and expectations. These forward-looking statements
include statements regarding the timing of the pharmacokinetic
(PK) study of Gimoti and submission of a new drug application
(NDA), the potential approval and commercialization of Gimoti as
a new and effective treatment for gastroparesis, the potential
market size for Gimoti, the potential for Gimoti to be the only
product that has shown symptomatic efficacy in an endpoint,
Evokes protection of its intellectual property and Evokes belief
that the PK study may serve as a basis for submission of a
NDA.The inclusion of forward-looking statements should not be
regarded as a representation by the Company that any of its plans
will be achieved. Actual results may differ from those set forth
in this press release due to the risks and uncertainties inherent
in the Companys business, including, without limitation: the
statistically-significant data from the Phase 3 clinical trial of
Gimoti only includes a portion of the patients in trial and that
the Phase 3 trial failed to reach its primary endpoint; risks
associated with successfully commencing and receiving favorable
results from the planned PK study; later developments with the
Food and Drug Administration (FDA) that may be inconsistent with
the already completed pre-NDA meetings, including that the FDA
will not accept selected data from our Phase 3 clinical trial;
the FDA may change its recommendations regarding evaluation of
drugs for the treatment of gastroparesis; the inherent risks of
clinical development of Gimoti; Evoke is entirely dependent on
the success of Gimoti, and Evoke cannot be certain that it will
be able to submit an NDA for Gimoti or obtain regulatory approval
for or successfully commercialize Gimoti; risks associated with
manufacturing new formulations of Gimoti for use in the PK trial;
Evokes dependence on third parties for the manufacture of Gimoti
as well as the conduct of the PK trial; Evoke may require
additional funding to complete the PK study and submit the NDA,
and will require substantial additional funding to commercialize
Gimoti, and may be unable to raise capital when needed, including
to fund ongoing operations; Evoke may not be able to successfully
commercialize Gimoti, if approved, as a result of risks
associated with market acceptance, coverage and reimbursement and
competing products; and other risks detailed in the periodic
reports Evoke files with the Securities and Exchange
Commission.You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof, and the Company undertakes no obligation to revise or
update this report to reflect events or circumstances after the
date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement. This caution is made
under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

About EVOKE PHARMA, INC. (NASDAQ:EVOK)

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

EVOKE PHARMA, INC. (NASDAQ:EVOK) Recent Trading Information

EVOKE PHARMA, INC. (NASDAQ:EVOK) closed its last trading session down -0.05 at 2.66 with 959,187 shares trading hands.